TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Biopharmacon, AB
Closing information (x1000 EUR)
| Closing information | 2025/06 | 2024/06 | 2023/06 |
| Turnover |
33
|
42
|
32 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
9
|
20
|
2 |
| EBITDA |
-5
|
5
|
-3 |
| Total assets |
631
|
623
|
577 |
| Current assets |
594
|
586
|
542 |
| Current liabilities |
8
|
15
|
7 |
| Equity capital |
619
|
601
|
564 |
| - share capital |
9
|
9
|
8 |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2025/06 | 2024/06 | 2023/06 |
| Solvency |
98.1%
|
96.5%
|
97.7% |
| Turnover per employee |
33
|
42
|
32 |
| Profit as a percentage of turnover |
27.3%
|
47.6%
|
6.2% |
| Return on assets (ROA) |
1.4%
|
3.2%
|
0.3% |
| Current ratio |
7425.0%
|
3906.7%
|
7742.9% |
| Return on equity (ROE) |
1.5%
|
3.3%
|
0.4% |
| Change turnover |
-10
|
9
|
12 |
| Change turnover % |
-24%
|
26%
|
57% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/06 | 2024/06 | 2023/06 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.